Delivery Order SPE2DB24D2101-SPE2DB25FKNTU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at approximately $40,911 to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 25, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $36,944.08 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, competitively awarded delivery order represents a direct fulfillment under the company's existing pharmaceutical supply agreement with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on July 31, 2025, with an ultimate completion date of August 1, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $7,947.84. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $15.5K to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injections, with a ceiling value of $20,906.28 under a firm fixed-price contract. This non-set-aside delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply framework with DLA and is scheduled for completion by August 12, 2025. The pharmaceutical will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $12,307.65. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This...
- The Defense Logistics Agency awarded a $27,227.34 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen auto-injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 5, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order serves the Defense...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNTUDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $27,045.49. This is a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and represents a non-competitive set-aside. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal healthcare systems. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that supports military healthcare programs globally. AmerisourceBergen is a critical supplier within the federal pharmaceutical supply chain, regularly fulfilling orders for a comprehensive range of medications and medical supplies across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. The company's contract history demonstrates consistent capability in delivering both brand-name and generic pharmaceuticals through competitively awarded, firm fixed-price arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.0k | 8/22/25 |